Treatment outcomes stratified by number and type of HR*
| Variable | Low (0), immunological HR (n=86) | Intermediate (1 or 2), immunological HR (n=46) | High (>3), immunological HR (n=5) | P value | |
| 1 month outcomes | Reduction in average NRS back pain score from baseline (mean±SD) | 1.2±2.0 | 0.3±2.6 | 1.2±3.3 | 0.11 |
| Reduction in worst NRS back pain score from baseline (mean±SD) | 1.6±2.5 | 1.7±2.8 | 2.2±4.4 | 0.85 | |
| Reduction in average NRS leg pain score from baseline (mean±SD) | 1.7±2.2 | 1.0±3.3 | 0.6±3.8 | 0.23 | |
| Reduction in worst NRS leg pain score from baseline (mean±SD) | 2.5±2.7 | 1.9±3.0 | 1.8±4.7 | 0.54 | |
| Reduction in ODI score (mean±SD) | 5±13 | 3±16 | 9±19 | 0.60 | |
| Medication reduction (n%)† | 29/78 (37%) | 14/43 (33%) | 1/5 (20%) | 0.68 | |
| Satisfaction score (mean±SD)‡ | 3.3±1.4 | 3.3±1.5 | 2.5±1.7 | 0.47 | |
| Positive outcome (n%)§ | 38 (44%) | 19 (41%) | 1 (20%) | 0.56 | |
| 3 month outcomes | Reduction in average NRS Back pain score from baseline (mean±SD) | 0.8±1.9 | 0±2.6 | 0.8±2.5 | 0.12 |
| Reduction in worst NRS back pain score from baseline (mean±SD) | 1.0±2.1 | 1.0±2.4 | 1.6±3.0 | 0.82 | |
| Reduction in average NRS leg pain score from baseline (mean±SD) | 1.2±2.1 | 0.5±3.0 | −0.2±2.2 | 0.15 | |
| Reduction in worst NRS leg pain score from baseline (mean±SD) | 1.8±2.4 | 1.4±2.6 | 0.6±2.2 | 0.45 | |
| Reduction in ODI score (mean±SD) | 3±13 | 2±16 | 5±12 | 0.88 | |
| Medication reduction (n%)† | 28/78 (36%) | 13/43 (30%) | 1/5 (20%) | 0.67 | |
| Satisfaction score (mean±SD)‡ | 3.3±1.4 | 3.2±1.5 | 2.3±1.3 | 0.36 | |
| Positive outcome (n%)§ | 28 (33%) | 12 (26%) | 1 (20%) | 0.73 | |
| Variable | High (0), non-immunological HR (n=86) | Intermediate (1 or 2), non-immunological HR (n=34) | High (>3), non-immunological HR (n=17) | P value | |
| 1 month outcomes | Reduction in average NRS back pain score from baseline (mean±SD) | 1.3±2.1 | 0.4±2.7 | 0.4±2.1 | 0.11 |
| Reduction in worst NRS back pain score from baseline (mean±SD) | 1.9±2.7 | 1.2±2.7 | 0.9±2.6 | 0.23 | |
| Reduction in average NRS leg pain score from baseline (mean±SD) | 1.7±2.5 | 1.6±3.0 | −0.2±2.3 | 0.002 | |
| Reduction in worst NRS leg pain score from baseline (mean±SD) | 2.6±2.6 | 2.3±3.4 | 0.6±2.9 | 0.036 | |
| Reduction in ODI score (mean, SD) | 6±15 | 3±12 | 0±16 | 0.28 | |
| Medication reduction (n%)† | 30/78 (38%) | 11/32 (34%) | 3/16 (19%) | 0.32 | |
| Satisfaction score (mean±SD)‡ | 3.6±1.3 | 3.0±1.6 | 2.2±1.4 | <0.001 | |
| Positive outcome (n%)§ | 44 (51%) | 12 (35%) | 2 (12%) | 0.007 | |
| 3 month outcomes | Reduction in average NRS back pain score from baseline (mean±SD) | 0.7±2.1 | 0.3±2.7 | 0.2±1.7 | 0.55 |
| Reduction in worst NRS back pain score from baseline (mean±SD) | 1.2±2.2 | 0.8±2.5 | 0.6±2.0 | 0.61 | |
| Reduction in average NRS leg pain score from baseline (mean±SD) | 1.1±2.5 | 1.1±2.5 | −0.4±1.7 | 0.048 | |
| Reduction in worst NRS leg pain score from baseline (mean±SD) | 1.9±2.5 | 1.6±2.6 | 0.1±1.5 | 0.030 | |
| Reduction in ODI score (mean±SD) | 3±15 | 3±13 | 1±13 | 0.49 | |
| Medication reduction (n%)† | 29/78 (37%) | 10/32 (31%) | 3/16 (19%) | 0.35 | |
| Satisfaction score (mean±SD)‡ | 3.5±1.3 | 2.9±1.5 | 2.2±1.3 | <0.001 | |
| Positive outcome (n%)§ | 30 (35%) | 10 (29%) | 1 (6%) | 0.058 | |
*Designation of immunological or non-immunological based on physician designation in the absence of lab tests or other documentation (eg, medical record of event).
†Medication reduction defined as greater than 20% decrease in opioid consumption or cessation of non-opioid analgesic.
‡Satisfaction measured on 1–5 Likert scale with higher scores indicating greater satisfaction.
§Designated as two point or greater decrease in average leg pain score coupled with >3 score on the five-point satisfaction scale.
HR, hypersensitivity reactions; NRS, numerical rating scale; ODI, Oswestry Disability Index.